Periodic Benefit-Risk Evaluation Report (PBRER)

According to European Medicaments Agency (EMA) guidelines, already implemented since 2012; Marketing Authorization Holders (MAHs) have to submit periodic updated safety reports following GVP Module VII. The objective of this submission is to harmonise all the existing information relating to every single medicinal product; in order to update their risk-benefit profile. This strategy allows EMA…